九洲药业(603456.SH)子公司获得甲苯磺酸艾多沙班药品注册证书

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has received the drug registration certificate for Edoxaban Tosilate Tablets from the National Medical Products Administration [1] Group 1: Company Developments - Jiuzhou Biopharmaceutical has been granted approval for Edoxaban Tosilate, an oral anticoagulant [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] - Edoxaban Tosilate was originally developed by Daiichi Sankyo in Japan and was launched in Japan in April 2011 [1] Group 2: Industry Context - Other manufacturers in China that have obtained registration for Edoxaban include Hainan Sinopharm and Shandong New Era Pharmaceutical [1]